Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study
- PMID: 12893206
- DOI: 10.1016/s0090-8258(03)00278-6
Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study
Abstract
Objective: The purpose of this study was to determine the relative influences of the extent of disease present before surgery and completeness of cytoreduction on survival for patients with advanced ovarian cancer.
Methods: Patients (408) with stage IIIC epithelial ovarian cancer had cytoreductive surgery before systemic platinum-based combination chemotherapy. A ranking system (0-3) was devised to prospectively quantify the extent of disease involving: (1) right upper quadrant (diaphragm/hepatic, and adjacent peritoneal surfaces), (2) left upper quadrant (omentum/gastro-colic ligament, spleen, stomach, transverse colon, splenic flexure of colon), (3) pelvis (reproductive organs, recto-sigmoid, pelvic peritoneum), (4) retroperitoneum (pelvic/aortic nodes), and (5) central abdomen (small bowel, ascending/descending colon, mesentery, anterior abdominal wall, pericolic gutters). Survival was analyzed (log rank and Cox regression) on the basis of the rankings at these anatomic regions, the sum of intraabdominal rankings, and the cytoreductive outcome.
Results: Overall median and estimated 5-year survivals were 58.2 months and 49%. On univariate analysis, the central abdominal (P = 0.008) and left upper quadrant (P = 0.03) rankings, the sum of rankings (P = 0.01), and the cytoreductive outcome (P </= 0.0001) influenced survival (log rank). Survival was independently (stepwise Cox model) influenced by the sum of rankings (0-5, RR 1.00; 6-10, RR 1.24; 11-15, RR 1.44; P = 0.05), and completeness of cytoreduction (visibly disease-free, RR 1.00; </=1 cm residual, RR 2.32; >1 cm residual, RR 2.98; P = 0.001).
Conclusions: Cytoreduction to a visibly disease-free outcome has a more significant influence on survival than the extent of metastatic disease present before surgery. Operative efforts should not be abbreviated on the hypothesis that extensive disease at specific anatomic regions precludes long-term survival.
Similar articles
-
Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival?Gynecol Oncol. 2001 Sep;82(3):435-41. doi: 10.1006/gyno.2001.6313. Gynecol Oncol. 2001. PMID: 11520137
-
Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.Gynecol Oncol. 1998 May;69(2):103-8. doi: 10.1006/gyno.1998.4955. Gynecol Oncol. 1998. PMID: 9600815
-
Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer.J Surg Oncol. 2000 Sep;75(1):24-30. doi: 10.1002/1096-9098(200009)75:1<24::aid-jso5>3.0.co;2-l. J Surg Oncol. 2000. PMID: 11025458
-
Advanced ovarian cancer.Curr Treat Options Oncol. 2001 Apr;2(2):109-18. doi: 10.1007/s11864-001-0053-1. Curr Treat Options Oncol. 2001. PMID: 12057129 Review.
-
"Optimal" cytoreduction for advanced epithelial ovarian cancer: a commentary.Gynecol Oncol. 2006 Oct;103(1):329-35. doi: 10.1016/j.ygyno.2006.07.004. Epub 2006 Jul 31. Gynecol Oncol. 2006. PMID: 16876853 Review.
Cited by
-
Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182.J Clin Oncol. 2015 Mar 10;33(8):937-43. doi: 10.1200/JCO.2014.56.3106. Epub 2015 Feb 9. J Clin Oncol. 2015. PMID: 25667285 Free PMC article.
-
Rectosigmoid sparing en bloc pelvic resection for fixed ovarian tumors: Surgical technique and perioperative and oncologic outcomes.Front Oncol. 2022 Aug 22;12:980050. doi: 10.3389/fonc.2022.980050. eCollection 2022. Front Oncol. 2022. PMID: 36072802 Free PMC article.
-
Role of primary surgery in advanced ovarian cancer.World J Surg Oncol. 2004 Oct 2;2:32. doi: 10.1186/1477-7819-2-32. World J Surg Oncol. 2004. PMID: 15461788 Free PMC article.
-
Uterine metastases in ovarian carcinoma: frequency and survival in women who underwent hysterectomy.J Gynecol Oncol. 2010 Sep;21(3):191-5. doi: 10.3802/jgo.2010.21.3.191. Epub 2010 Sep 28. J Gynecol Oncol. 2010. PMID: 20922143 Free PMC article.
-
Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancer.J Ovarian Res. 2010 Oct 12;3:22. doi: 10.1186/1757-2215-3-22. J Ovarian Res. 2010. PMID: 20939881 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical